The pages published at Sermorelin Therapy Editorial are written for general information and education. They describe how sermorelin therapy and related growth hormone releasing peptides are discussed in the medical literature, how regulatory pathways for compounded medications work in the United States, and what a typical clinical workflow looks like when a licensed clinician evaluates an adult patient. The site does not provide medical advice and must not be treated as a substitute for a personal consultation.
Not medical advice. Nothing on this site constitutes a diagnosis, a treatment recommendation, a prescription, a dosing instruction, or any other form of individualised medical opinion. The editors are not your physicians. Reading an article on Sermorelin Therapy Editorial does not create a clinician-patient relationship, an evaluator-patient relationship, or any other kind of professional duty of care from us to you. If you are considering sermorelin therapy or any other peptide protocol, you must consult a clinician who is licensed in your state, who can take a full history, examine you, order appropriate laboratory testing, and prescribe (or decline to prescribe) based on your individual circumstances.
Consult a licensed United States clinician. Sermorelin is a compounded medication that may only be dispensed in the United States by a licensed pharmacy on the order of a clinician authorised to prescribe in the patient’s state of residence. State requirements vary. Telemedicine rules, controlled-substance rules, and compounding rules also vary across jurisdictions. Do not rely on this site to navigate any of that. Speak to a clinician who holds an active United States licence in your state, ask them about their training in endocrinology and peptide therapy, and let them — not a website — decide whether sermorelin is appropriate for you.
Regulatory context is general background only. The site discusses how the FDA, state boards of pharmacy, USP standards for compounded sterile preparations, and DEA scheduling decisions interact with the compounded peptide marketplace. That material is offered as broad context so that readers can follow the news, understand a clinician’s references, and ask informed questions during a real appointment. It is not legal advice, not regulatory advice, and not a substitute for guidance from a licensed clinician, attorney, or compounding pharmacist who knows your situation.
Clinical processes described in articles. Where pages describe a clinical workflow — for example, screening laboratory panels, IGF-1 monitoring, dose-titration considerations, or contraindications — those descriptions reflect the published literature and the routine practice patterns reported by clinicians who treat adult growth hormone insufficiency. They are illustrative. Your clinician may follow a different protocol, may use different reference ranges, and may reach different conclusions for entirely valid reasons. Trust your clinician, not a general-interest article.
Off-label and investigational discussion. Some peptides and applications referenced on the site are discussed in an off-label or investigational context within the clinical literature. Mentioning a topic on Sermorelin Therapy Editorial does not endorse it, does not imply that it is approved by the FDA for a particular use, and does not imply that any specific reader should pursue it.
Emergencies. If you are experiencing a medical emergency, call 911 or go to the nearest emergency department. Do not use this site, the contact form, or the editorial inbox to report an urgent clinical problem. We do not monitor messages in real time and we are not able to provide emergency assistance.
External links. Links to outside resources are provided as a courtesy. We do not control those sites and we are not responsible for changes to their content after we link to them.
Questions. Comments about a specific article, including corrections, can be sent to Sermorelin Therapy Editorial using the page. Editorial address: Sermorelin Therapy Editorial
1209 Orange Street
Wilmington, DE 19801
United States. Phone: +1 (302) 555-0148.
The brief in the United States, USA
Sermorelin is a synthetic 29 amino acid peptide that copies the first portion of natural growth hormone releasing hormone. Administered as a small subcutaneous injection at night, it signals the pituitary gland to release the body's own growth hormone in a pulsatile, physiologic rhythm. That mechanism is the entire reason adults consider it.
Unlike injected human growth hormone, sermorelin keeps the body's natural feedback loop intact. The pituitary continues to regulate output. Levels rise within a window that resembles a younger adult's overnight pulse, then fall. Recovery, sleep depth, body composition and skin quality are the outcomes most commonly described.
For adults across the United States, USA, sermorelin is dispensed exclusively as a compounded preparation by licensed 503A and 503B pharmacies, after a US-licensed clinician writes a prescription. The branded sermorelin product approved decades ago was discontinued. The current treatment requires a real consultation, a real lab panel, and a real prescription. None of that is bypassed by telehealth.
Mechanism, in plain words
Natural growth hormone is released by the pituitary in short overnight pulses. With age, the size and frequency of these pulses fall. Output at 55 looks nothing like output at 25. Most of the visible age signals associated with growth hormone decline, from softer sleep to slower healing to gradual fat redistribution, follow from that drop.
Sermorelin asks the pituitary to do its old job. It binds the same receptor that natural GHRH binds, and triggers the same release. Because the body's negative feedback loop remains in place, sermorelin cannot push growth hormone past the body's own safety ceiling. This is the structural reason it is generally considered safer than injected synthetic HGH.
What it is not
Sermorelin is not anabolic in the way testosterone is anabolic. It is not a fat loss drug. It is not a performance enhancer, and is not legally prescribed for that purpose. It is not a substitute for sleep, training, or protein. It is also not a quick result. The body needs months to fully translate restored GH pulses into measurable change.
Where the evidence sits
The clinical record on sermorelin runs back to the late 1970s, when GHRH-29 was first synthesized. Trials in growth hormone deficient children supported FDA approval of the branded form. In adults, the strongest peer-reviewed evidence covers a narrower set of outcomes, primarily IGF-1 response, body composition changes over 12 to 24 weeks, and self-reported sleep and recovery quality.
Three considerations belong in any honest reading. First, modern compounded sermorelin is not a separately approved drug. Second, most public testimonials on the wellness side conflate sermorelin with the broader peptide stack patients also use. Third, the published evidence does not support sermorelin as a cosmetic anti-aging treatment, and credible providers do not market it as one.
Sermorelin is a tool for restoring physiologic pulses, not a tool for pushing growth hormone past where the body would naturally take it. The clinical case is honest only when framed that way.
The standard protocol
A first cycle generally runs 12 weeks, with a follow-up IGF-1 lab drawn at the end. Doses are dialed by the prescribing clinician based on baseline labs, body weight, and tolerance. The most common pattern in current US telehealth practice looks like this.
- Intake and baseline labHealth questionnaire on energy, sleep, recovery, training, sexual function. Baseline IGF-1, fasting glucose, complete metabolic panel, lipid panel.
- Clinician reviewA licensed clinician confirms medical appropriateness. If not appropriate, the consultation is refunded. If appropriate, dose is calculated.
- DispensingCompounded sermorelin acetate is mailed from a 503A or 503B partner pharmacy with insulin syringes, alcohol pads, sharps container.
- Self-administrationSingle subcutaneous injection at night, on an empty stomach. Standard schedule, five nights on and two nights off. Twelve weeks.
- ReassessmentFollow-up IGF-1 at week 12. Dose held, raised, lowered, or paused based on labs and self-reported response.
How to obtain a real prescription
Legitimate sermorelin in the United States moves through a narrow channel. A licensed clinician in your state writes a prescription to a registered compounding pharmacy. Anything outside that channel, especially products purchased from research peptide vendors without prescription, sits outside the medical and legal model.
The telehealth provider referenced on this site operates in all 50 states, runs the intake through a licensed clinician, uses 503A and 503B partner pharmacies, and issues a full refund if the clinical decision is that sermorelin is not appropriate. That last point matters. A provider unwilling to refuse a prescription is not practicing medicine.
Questions readers ask
Is sermorelin FDA approved?
The original branded sermorelin product was approved and is no longer sold. The form prescribed today is a compounded preparation made by licensed pharmacies under sections 503A and 503B. Compounded preparations are not separately FDA approved, and that is disclosed at consultation.
How is this different from HGH?
HGH is the growth hormone molecule itself, supplied externally. Sermorelin is a releasing peptide that prompts the body's own pituitary to make growth hormone. Sermorelin preserves the body's natural ceiling. HGH does not.
What results do adults actually report?
The most consistent reports are improved sleep depth in the first four weeks, recovery and skin quality in the second month, and body composition with modest fat loss and small lean mass gains in months three and four. Libido and joint comfort are commonly mentioned later in the cycle.
Is it safe?
Reported side effects are generally mild, the most common being mild injection site redness, transient flushing, and occasional headache. Because sermorelin works through the body's own pituitary, the negative feedback loop limits supraphysiological exposure. Clinical contraindications are screened during intake.
What does a course cost?
A standard 12 week program through US telehealth typically runs between 180 and 240 dollars per month, including the clinician visit, labs, the medication, and supplies. HSA and FSA cards are accepted at most providers. Insurance generally does not cover compounded peptides.
Is the prescription legitimate?
Yes if the provider is a licensed telehealth network using a clinician licensed in your state and a registered compounding pharmacy. A copy of the prescription accompanies the shipment. Off-channel research peptide vendors are not part of this model.
Is sermorelin legal where I live?
Sermorelin is legal across the United States when prescribed by a US-licensed clinician. The compounded preparation is dispensed under federal sections 503A and 503B, and the prescription is written by a clinician licensed in your jurisdiction.
Speak with a licensed clinician in the United States, USA
Online intake, blood panel, a real clinical decision. If sermorelin is not for you, you are not prescribed it.
Start your consultation